The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2024Developing a Binding Assay to Detect Toxic Alpha-synuclein Aggregates in Cerebrospinal Fluid and Plasma
Study Rationale: The formation of toxic protein aggregates is an early step in the pathology of several neurodegenerative disorders, including Parkinson’s disease (PD). Using computer simulations, we...
-
Research Grant, 2024(SUPPLEMENT) Investigation of Small Molecules for Rescuing Lysosomal and GBA1 Deficiencies in GBA-associated Parkinson’s Disease
Study Rationale: Individuals with mutations in the GBA1 gene encoding the enzyme β-glucocerebrosidase (GCase) have a higher risk of Parkinson’s disease (PD). Gaucher disease, a rare genetic disease...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Interrogating Novel Defects in Protein Glycosylation in GBA1-associated Parkinson’s Disease
Study Rationale: Sugars are added to proteins in a process called glycosylation. The precise manner in which these sugars are added is critical for the proper function of the resulting glycoproteins...
-
Alpha-synuclein Seed Amplification Assay Program, 2024Maximizing Sensitivity of Alpha-synuclein Seed Amplification Assays by Eliminating Spontaneous Aggregation
Study Rationale: A key characteristic of Parkinson’s disease (PD) is the formation of alpha-synuclein aggregates in the brain. The ability to detect these aggregates in body fluids is important for...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Assessing the Safety and Efficacy of a Novel Enzyme Inhibitor in Reducing Neuroinflammation and Enhancing Neuroprotection in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by neuroinflammation and the loss of dopamine neurons. Recently, epoxy-fatty acids have been shown to be neuroprotective in preclinical...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Assessment of Psilocybin Therapy for Treatment of Depression in Parkinson’s Disease
Study Rationale: Depression is of the most common and disabling symptoms of Parkinson’s disease (PD), and it is linked to poor quality of life and faster disease progression. Unfortunately, we lack...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.